Ossiam’s Nektar Therapeutics NKTR Stock Holding History

Ossiam’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-145	Closed	-$40K	–	501
2019 Q3	$40K	Buy	+145	New	+$53.2K	﹤0.01%	433

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Ossiam's NKTR Position: Q4 2019 in Review

Ossiam sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 145 shares — an estimated $40K sold.

Ossiam first reported a position in NKTR in Q3 2019 and held it in 1 quarter. The position peaked at $40K in Q3 2019. 280 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

Ossiam reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
Ossiam sold 145 Nektar Therapeutics shares in Q4 2019, an estimated $40K.
Ossiam first reported a position in Nektar Therapeutics in Q3 2019 and held it in 1 quarter.
Ossiam's Nektar Therapeutics position peaked at $40K in Q3 2019.
280 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Ossiam's 13F filing for Q4 2019, filed 14 Feb 2020.